Emoxypine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Emoxypine
2-Ethyl-6-methyl-3-hydroxypyridine.svg
Emoxypine ball-and-stick.png
Clinical data
Trade names Mexidol
Synonyms Emoxipine, Emoxypin, Epigid, 6-Methyl-2-ethyl-3-hydroxypyridine
Routes of
administration
Oral & IV
ATC code
  • none
Legal status
Legal status
  • US: Unscheduled; not FDA approved
  • RU: Rx only
Pharmacokinetic data
Biological half-life 2-2.6 h
Identifiers
CAS Number
PubChem CID
ChemSpider
ECHA InfoCard 100.205.098
Chemical and physical data
Formula C8H11NO
Molar mass 137.179 g/mol
3D model (JSmol)
Melting point 170 to 172 °C (338 to 342 °F) [1]
  (verify)

Emoxypine (2-ethyl-6-methyl-3-hydroxypyridine), also known as Mexidol or Mexifin when used as the succinate salt, is an antioxidant manufactured in Russia by Pharmasoft Pharmaceuticals.[2] Its chemical structure resembles that of pyridoxine (a type of vitamin B6). It is not approved for any medical use in the United States or Europe.

History[edit]

Emoxypine was first synthesized by L.D. Smirnov and K.M. Dumayev, then studied and developed in the Institute of Pharmacology, Russian Academy of Medical Sciences and National Scientific Center of Bioactive Substances Safety.[3]

Use[edit]

In Russia, emoxypine has a wide range of applications in medical practice. It purportedly exercises anxiolytic,[4][5] anti-stress, anti-alcohol, anticonvulsant, nootropic, neuroprotective and anti-inflammatory action.[citation needed] Emoxypine presumably improves cerebral blood circulation, inhibits thrombocyte aggregation, lowers cholesterol levels, has cardioprotective and antiatherosclerotic action.[3][medical citation needed]

Mechanism of action[edit]

Emoxypine's mechanism of action is believed to be its antioxidant and membrane-protective effects with the following key components:[3][6][medical citation needed]

Clinical study[edit]

One study determined the effectiveness of emoxypine in 205 patients with clinical manifestations of lumbosacral radiculopathy (LSR). Patients were divided into two groups, and further were divided into subgroups depending on the presence of motor disturbances. All patients received a course of conventional medical treatment and physiotherapy; main group additionally received emoxypine. Thereafter, clinical-neurological control of long-term results of treatment in subgroups of patients was performed. The results showed that the use of emoxypine in the combined therapy of patients with LSR led to significant and persistent reduction of severity of pain syndrome and rapid recovery of function of spinal roots and peripheral nerves compared with conventional therapy.[3][7]

References[edit]

  1. ^ W. Gruber (1953). "Synthesis of 3-Hydroxy-2-alkylpyridines". Canadian Journal of Chemistry. 31 (6): 564–568. doi:10.1139/v53-079. 
  2. ^ mexidol.ru, Pharmasoft Website
  3. ^ a b c d e Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia http://www.mexidol.ru/en/pro/library/farmacology/item102573
  4. ^ I. A. Volchegorskii; et al. (April 2015). "Comparative Analysis of the Anxiolytic Effects of 3-Hydroxypyridine and Succinic Acid Derivatives". Bulletin of Experimental Biology and Medicine. 158 (6): 756–761. doi:10.1007/s10517-015-2855-3. 
  5. ^ S. A. Rumyantseva A.; I. Fedin; O. N. Sokhova (October 2012). "Antioxidant Treatment of Ischemic Brain Lesions". Neuroscience and Behavioral Physiology. 42 (8): 842–845. doi:10.1007/s11055-012-9646-3. 
  6. ^ Dumayev K.M., Voronina T.A., Smirnov L.D. antioxidants in the prophylaxis and therapy of CNS pathologies. Moscow, 1995
  7. ^ Likhacheva, EB; Sholomov, II (2006). "Clinical and immunological assessment of efficacy of mexidol in the treatment of lumbosacral radiculopathy". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov \i] Vserossiiskoe obshchestvo psikhiatrov. 106 (10): 52–7. PMID 17117675.